These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free
An apparent leak prompted Merck and Moderna to release the full trial results ahead of schedule, but investors puzzlingly greeted the good news by sending the companies’ stock prices down.
This is a summary aggregated from Gizmodo. Read the complete article on the original site:
Read full article at Gizmodo
